Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-01-27 Capital/Financing Update
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
HCA to invest US$4 million in Ondine
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Ondine Biomedical Inc. regarding a new equity investment of US$4 million from HCA Healthcare, Inc. It details the issuance of new common shares, the impact on share capital, and the total voting rights. This falls under the category of capital raising and financing activities. While it mentions voting rights, it is primarily a capital/financing update rather than a simple voting results declaration. Therefore, it is classified as a Capital/Financing Update (CAP).
2025-01-27 English
Ondine recruits first patient for US Phase 3 trial
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces a specific operational milestone: the recruitment of the first patient for a Phase 3 clinical trial. It does not fit into specific categories like financial reports, dividend announcements, or board changes. As it is a general corporate announcement regarding business operations and clinical trial progress, it falls under the 'Regulatory Filings' (RNS) category.
2024-12-30 English
Ondine commencing US Phase 3 clinical trial
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Ondine Biomedical Inc. commencing a Phase 3 clinical trial. It is a corporate news release detailing operational progress and regulatory status (FDA approval to start the trial). Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a standard regulatory announcement, it is classified as RNS.
2024-12-17 English
Notification of Major Holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for disclosing significant changes in share ownership (crossing thresholds). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2024-11-25 English
Notification of Major Holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Ondine Biomedical Inc. It explicitly details the acquisition or disposal of voting rights and the resulting percentage of voting rights held by a shareholder (Albemarle Life Sciences Fund). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2024-11-22 English
Director Holdings
Director's Dealing Classification · 100% confidence The document is an RNS announcement from Ondine Biomedical Inc. titled 'Director Holdings'. It provides a table detailing the shareholdings of various directors following a fundraising event. This falls under the category of 'Director's Dealing' (DIRS), as it reports the updated share ownership positions of company directors.
2024-11-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.